May 14, 2019 10:12 JST

Source: NEC Corporation

NEC Becomes the First Japanese Company to Join the TESLA Consortium's Fight Against Cancer

TOKYO, May 14, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaborative includes scientists from more than 35 of the leading neoantigen research groups in academia, nonprofit and industry. The goal is to find the best algorithms to predict which cancer neoantigens encoded in DNA and RNA can be recognized by and stimulate an immune response.

Individualized neoantigen vaccines, which are tailored to each patient's tumor, are one of most advanced cancer treatments to show great promise for activating the immune system to fight cancer whilst reducing the chances of autoimmune responses.

NEC was accepted into the TESLA consortium given the uniqueness of the company's Neoantigen Prediction System. The prediction system utilizes NEC's cutting-edge AI technology, "NEC the WISE"(1), to identify and prioritize patient-specific neoantigens. NEC comprehensively evaluates candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.

"By participating in this consortium, NEC will be able to collaborate with the world's leading research organizations and potentially improve the chances of survival for cancer patients with this new treatment option," said Osamu Fujikawa, Senior Vice President, NEC Corporation. "NEC focuses on the provision of social solutions and continues efforts to strengthen its next-generation healthtech businesses," he added.

(1) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.

Contact:
NEC
Seiichiro Toda        
s-toda@cj.jp.nec.com
+81-3-3798-6511
Source: NEC Corporation
Sectors: Enterprise IT, BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
December 19 2025 02:06 JST
 
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
December 15 2025 18:41 JST
 
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
December 15 2025 18:04 JST
 
Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz
December 12 2025 18:59 JST
 
NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries
December 12 2025 17:13 JST
 
NEC Named to CDP's "A List" for Climate Change and Water Security for the Seventh Consecutive Year
December 11 2025 18:00 JST
 
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
December 10 2025 11:00 JST
 
NEC Wins TIP MUST Silver Badge with Advanced Network Operating System for Open Optical Transponders
December 09 2025 12:39 JST
 
NEC Orchestrating Future Fund Invests in PopID, Inc. to Accelerate Global Expansion of Biometric Payment Solutions and Launch a Strategic Collaboration
December 04 2025 17:52 JST
 
NEC Launches AI Agent Service in Japan to Automate Procurement Negotiations Using AI
December 02 2025 22:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>